VLA-1601
- Generic Name
- VLA-1601
Inventiva Restructures to Focus on MASH Drug Development, Reports €96.6M Year-End Cash Position
• Inventiva announces strategic pipeline prioritization, halting all preclinical research to focus exclusively on lanifibranor development for MASH treatment, with planned 50% workforce reduction.
• Company reports €96.6 million cash position at 2024 year-end, securing operations until Q3 2025, with potential additional funding of €116 million expected in Q2 2025.
• Last patient screening completed in NATiV3 Phase 3 trial of lanifibranor, with final patient randomization expected in first half of 2025 and topline results anticipated in second half of 2026.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath